InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,214.80
(
0.00%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.34
(
-0.16%
)
Bitcoin
60,708.09
(
-0.17%
)
Post# of 108192
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cdiddy01

Send PM Follow Ignore
Followers 1
Posts 972
Boards Moderated 0
Alias Born 02/14/2018

cdiddy01

Re: None

Wednesday, 01/23/2019 4:13:27 PM

Wednesday, January 23, 2019 4:13:27 PM

Post# of 108192
This nightmare never ends. Strange hold by the fda nonetheless.

FDA’s review of the AXAL Investigational New Drug (IND) application was prompted by our proposal to modify the AIM2CERV trial’s analysis plan

I wonder whats new that they found after already reviewing it prior. Maybe we should have just left the trial design as is.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ADXS News
More ADXS News
InvestorsHub NewsWire

FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM

Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM

Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM

Start posting your company's news
Only $200 per official company press release!